BeOne Medicines’ Chan Lee proposes $1.17M ADS sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BeOne Medicines Ltd. (ONC) officer Chan Lee filed notice of a proposed sale of 2,895 ADS, with an aggregate market value of $1,168,422.00; the approximate sale date is November 19, 2026. The notice states Chan Lee acquired 2,895 ADS on November 19, 2026 through an exercise of stock options. It also identifies two prior 10b5-1 sales: 1,115 ADS on November 5, 2026, for gross proceeds of $446,909.95, and 1,115 ADS on September 30, 2026, for $418,125.00.
Key Figures
Key Terms
ADS technical
Rule 10b5-1 regulatory
Exercise of Stock Options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ADS is BeOne Medicines officer Chan Lee proposing to sell?
What prior 10b5-1 sales did Chan Lee report for BeOne Medicines (ONC)?
What 10b5-1 plan date is listed for Chan Lee's BeOne Medicines sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.